Activated neutrophils impair gastric cytoprotection role of neutrophil elastase.
Neutrophil elastase decreases production of PGI2 by cultured endothelial cells. Thus, neutrophil elastase may play an important role in gastric mucosal injury by decreasing the tissue level of PGI2, an important gastric cytoprotective substance. We examined whether activated neutrophils inhibit gastric PGI2 production in rats subjected to water-immersion restraint stress. Gastric 6-keto-PGF1alpha levels were determined by enzyme immunoassay. Gastric mucosal blood flow was determined by laser-Doppler flowmeter. Gastric microvascular permeability was determined by Evans blue leakage. Gastric levels of 6-keto-PGF1alpha were transiently increased 0.5 hr after the stress, followed by a decrease to below baseline at 6 hr, when mucosal blood flow fell to 60% of baseline. Gastric levels of 6-keto-PGF1alpha were significantly higher in animals with nitrogen mustard-induced leukocytopenia than in controls 1 and 6 hr after the stress. In leukocytopenic animals, levels 6 hr after stress were not lower than those preceding stress. Leukocytopenia markedly limited both the decrease in mucosal blood flow and the increase in gastric microvascular permeability. The level of gastric mucosal injury observed 6 hr after the stress was markedly attenuated by leukocytopenia. Pretreatment with neutrophil elastase inhibitors (ONO-5046 and Eglin C) or an anti-P-selectin monoclonal antibody produced effects similar to leukocytopenia. Neutrophil elastase is involved in the stress-induced gastric mucosal injury by decreasing gastric production of PGI2. Thus, pharmacologic inhibition of neutrophil elastase should help to prevent stress-induced gastric mucosal injury.
Harada
N
N
Department of Laboratory Medicine, Kumamoto University School of Medicine, Japan.
Okajima
K
K
Liu
W
W
Uchiba
M
M
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D019610:Cytoprotection / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D011464:Epoprostenol / Q000037:antagonists & inhibitors / Q000502:physiology*; D005753:Gastric Mucosa / Q000098:blood supply / Q000378:metabolism; D016285:Iloprost / Q000494:pharmacology; D007101:Immersion; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors / Q000502:physiology*; D007970:Leukopenia / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D009504:Neutrophils / Q000502:physiology*; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D012149:Restraint, Physical; D013270:Stomach / Q000473:pathology / Q000503:physiopathology*; D013272:Stomach Diseases / Q000209:etiology / Q000473:pathology / Q000503:physiopathology
D004791:Enzyme Inhibitors; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D009195:Peroxidase; D019272:Leukocyte Elastase; D016285:Iloprost